Suppr超能文献

高密度脂蛋白胆固醇在显性肝性脑病患者中的预后价值

Prognostic Value of High-Density Lipoprotein Cholesterol in Patients with Overt Hepatic Encephalopathy.

作者信息

Shi Ke, Bi Yufei, Wang Xiaojing, Li Yanqiu, Zeng Xuanwei, Feng Ying, Wang Xianbo

机构信息

Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

出版信息

Biomedicines. 2024 Aug 6;12(8):1783. doi: 10.3390/biomedicines12081783.

Abstract

Overt hepatic encephalopathy (OHE), a serious complication of liver cirrhosis, is associated with alterations in lipid and lipoprotein metabolism. We evaluated the correlation between high-density lipoprotein cholesterol (HDL-C) levels and transplant-free (TF) mortality in patients with OHE. Patients with OHE admitted to Beijing Ditan Hospital between January 2010 and August 2016 (n = 821) and between September 2016 and December 2020 (n = 480) were included in the training and validation sets, respectively. Independent predictors were explored by a multivariate Cox regression analysis, and the area under the receiver operating characteristic curve (AUC) was used to assess the prognostic value of these factors. The prognostic value of HDL-C was good (AUC at 1 year: 0.745) and was equivalent to that of the Model for End-Stage Liver Disease (MELD) score (AUC at 1 year: 0.788). The optimal threshold values for HDL-C and MELD were 0.5 mmol/L and 17, respectively. The 1-year TF mortality rates in the low-risk (HDL-C ≥ 0.5 mmol/L and MELD < 17) and high-risk (HDL-C < 0.5 mmol/L and MELD ≥ 17) groups were 7.5% and 51.5% in the training set and 10.1% and 48.2% in the validation set, respectively. HDL-C level < 0.5 mmol/L and MELD score > 17 can facilitate the identification of high-risk patients and provide a basis for timely treatment.

摘要

显性肝性脑病(OHE)是肝硬化的一种严重并发症,与脂质和脂蛋白代谢改变有关。我们评估了显性肝性脑病患者高密度脂蛋白胆固醇(HDL-C)水平与无移植(TF)死亡率之间的相关性。分别将2010年1月至2016年8月期间(n = 821)和2016年9月至2020年12月期间(n = 480)入住北京地坛医院的显性肝性脑病患者纳入训练集和验证集。通过多因素Cox回归分析探索独立预测因素,并使用受试者工作特征曲线下面积(AUC)评估这些因素的预后价值。HDL-C的预后价值良好(1年时AUC:0.745),与终末期肝病模型(MELD)评分的预后价值相当(1年时AUC:0.788)。HDL-C和MELD的最佳阈值分别为0.5 mmol/L和17。训练集中低风险(HDL-C≥0.5 mmol/L且MELD < 17)和高风险(HDL-C < 0.5 mmol/L且MELD≥17)组的1年无移植死亡率分别为7.5%和51.5%,验证集中分别为10.1%和48.2%。HDL-C水平< 0.5 mmol/L且MELD评分> 17有助于识别高风险患者,并为及时治疗提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e16/11351328/a9b50a022344/biomedicines-12-01783-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验